Skip to main content
    K

    Kiniksa Pharmaceuticals Ltd (KNSA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $94.23
    -2.10 (-2.18%)

    Market Cap: $7.57B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kiniksa Pharmaceuticals Ltd (KNSA) Financials: Revenue, Profit and Cash Flow

    Updated Oct 27, 2026. Financial statements from company filings, amounts in US dollars.

    Kiniksa Pharmaceuticals reported revenue of $677.56M for the fiscal year ended Dec 31, 2025, up 60.1% from the year before. That year, net income was $59.01M with a net margin of 8.7%, operating cash flow was $137.99M and free cash flow was $136.42M. The quarter ended Sep 30, 2026 had revenue of $285.97M and net income of $47.34M.

    Revenue and Margins

    The operating margin was 11.4% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$677.56M+60.1%54.7%11.4%8.7%
    Dec 2024$423.24M+56.6%55.3%-10.8%-10.2%
    Dec 2023$270.26M+22.7%66.7%-9.3%5.2%
    Dec 2022$220.18M+471.2%78.7%4.4%83.3%
    Dec 2021$38.54MN/A74.2%-406.4%-409.7%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 156.9% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$677.56M$423.24M$270.26M$220.18M$38.54M$0$0$0$0$0
    Cost of revenue$307.22M$189.22M$89.93M$46.97M$9.94M$0$0$0$0$22.00K
    Gross profit$370.35M$234.02M$180.33M$173.21M$28.61M$0$0$0$0-$22.00K
    Research and development$96.85M$111.62M$76.10M$65.49M$99.30M$112.04M$135.00M$86.60M$56.36M$17.44M
    Operating income$77.22M-$45.62M-$25.20M$9.77M-$156.64M-$157.36M-$169.96M-$108.16M-$65.40M-$24.00M
    Net income$59.01M-$43.19M$14.08M$183.36M-$157.92M-$161.38M-$161.87M-$103.23M-$64.87M-$23.97M
    EBITDA$89.51M-$34.02M-$15.38M$13.35M-$153.52M-$153.70MN/AN/A-$65.37M-$23.98M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$285.97M$243.60M$214.27M$202.13M$180.85M$156.80M$137.78M$122.54M$112.21M$108.63M$79.86M$83.39M
    Gross profit$152.38M$131.96M$117.89M$111.15M$97.29M$85.78M$76.13M$56.45M$62.80M$66.30M$48.47M$56.87M
    Operating income$54.24M$27.19M$29.27M$19.77M$24.02M$20.16M$13.27M-$19.30M-$9.66M-$117.00K-$16.54M$81.00K
    Net income$47.34M$25.43M$22.59M$14.20M$18.43M$17.83M$8.54M-$8.89M-$12.69M-$3.91M-$17.70M$25.24M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.99M by $162.61M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$763.63M$580.55M$526.32M$459.67M$232.80M$349.46M$254.53M$321.96M$47.49M$56.47M
    Current assets$527.18M$331.80M$276.30M$243.06M$196.45M$333.25M$241.63M$313.75M$47.10M$56.33M
    Cash and equivalents$165.60M$183.58M$107.95M$122.72M$122.47M$114.04M$46.93M$71.98M$45.55M$55.97M
    Total liabilities$196.03M$142.12M$87.48M$63.52M$47.76M$37.53M$29.11M$42.70M$17.43M$82.20M
    Short-term debt$2.99M$1.99M$2.25M$3.30M$3.38M$2.11M$1.70MN/AN/AN/A
    Shareholder equity$567.61M$438.44M$438.84M$396.15M$185.04M$311.94M$225.42M$279.27M-$89.71M-$25.73M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$983.24M$896.11M$825.28M$763.63M$712.33M$661.15M$599.33M$580.55M$555.30M$542.43M$519.67M$526.32M
    Total liabilities$273.05M$241.96M$219.59M$196.03M$176.95M$166.14M$141.84M$142.12M$118.29M$107.33M$87.78M$87.48M
    Cash and equivalents$81.66M$175.68M$189.95M$165.60M$174.86M$192.04M$157.13M$183.58M$97.38M$99.27M$141.08M$107.95M
    Shareholder equity$710.19M$654.15M$605.69M$567.61M$535.38M$495.01M$457.49M$438.44M$437.01M$435.10M$431.89M$438.84M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 98.9% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$137.99M$25.69M$13.30M$5.81M-$126.30M-$136.53M-$158.37M-$81.01M-$50.22M-$21.87M
    Capital expenditures$1.57M$430.00K$130.00K$105.00K$415.00K$283.00K$3.20M$5.29M$69.00K$3.00K
    Free cash flow$136.42M$25.26M$13.17M$5.70M-$126.71M-$136.81M-$161.57M-$86.30M-$50.29M-$21.87M
    Share repurchasesN/AN/AN/AN/AN/A$1.14M$118.00K$3.66M$0N/A
    Investing cash flow-$188.99M$37.67M-$29.56M-$8.08M$128.63M-$23.44M$49.21M-$239.20M-$69.00K-$3.00K
    Financing cash flow$33.02M$12.27M$1.50M$2.52M$5.88M$227.09M$84.11M$346.74M$39.87M$42.51M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$47.55M$47.20M$50.20M$53.89M$33.68M$28.09M$22.32M$18.77M-$2.24M$5.17M$3.99M$4.33M
    Capital expenditures$180.00K$663.00K$161.00K$633.00K$671.00K$165.00K$99.00K$346.00K$0$0$84.00K$56.00K
    Free cash flow$47.37M$46.53M$50.04M$53.26M$33.01M$27.93M$22.23M$18.42M-$2.24M$5.17M$3.90M$4.27M
    Last 12 quarters

    Frequently Asked Questions About KNSA

    What is Kiniksa Pharmaceuticals' annual revenue?

    Kiniksa Pharmaceuticals reported revenue of $677.56M for the fiscal year ended Dec 31, 2025.

    How fast is Kiniksa Pharmaceuticals' revenue growing?

    Revenue was up 60.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 45.5%.

    Is Kiniksa Pharmaceuticals profitable?

    Yes. Kiniksa Pharmaceuticals reported net income of $59.01M for the fiscal year ended Dec 31, 2025, with a net margin of 8.7%.

    How much free cash flow does KNSA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $137.99M minus capital expenditures of $1.57M produced free cash flow of $136.42M.

    How much debt does Kiniksa Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.99M and cash and equivalents of $165.60M.